Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm Phase II Trial to Evaluate the Safety and Efficacy of the Antibody-Drug Conjugate (ADC) SYD985 in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Endometrial Carcinoma Who Previously Progressed on or After First Line Platinum-based Chemotherapy

NCT04205630 is registered in ClinicalTrials.gov with Byondis B.V. as lead sponsor.

NCT NCT04205630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04205630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm Phase II Trial to Evaluate the Safety and Efficacy of the Antibody-Drug Conjugate (ADC) SYD985 in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Endometrial Carcinoma Who Previously Progressed on or After First Line Platinum-based Chemotherapy
Lead sponsor
Byondis B.V.
Phase
Phase 2
Overall status
Completed
Start date
May 28, 2020
Completion date
April 25, 2023
Enrollment
64 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer